BioCentury
ARTICLE | Clinical News

Comfyde carisbamate: Phase III data

December 15, 2008 8:00 AM UTC

A double-blind, international Phase III trial in 555 patients showed that both 200 and 400 mg/day doses of Comfyde missed the co-primary endpoints of median percent reduction in seizure frequency vs. ...